[Pattern dynamics of bacteriemia and sepsis pathogens in ICU patients of emergency service].
The results of microbiological tests of 2382 blood specimens from 698 patients of three ICUs of the N. V. Sklifosovsky Research Institute of Emergency Service were analysed for a period of 2009 to 2012. No microbial growth was detected in 1160 specimens (48.7%). In the subsequent tests 816 isolates were used. The quota of grampositive isolates in the pathogen pattern decreased from 51.68 to 35.9% and that of gramnegative isolates increased from 38.26 to 48.1%. The number of the Candida isolates increased from 7.38 to 15.2%. The frequency of the S. aureus and Enterococcus spp. isolates lowered from 26.2 to 13.3% and from 15.4 to 11.5% respectively. The quota of K. pneumoniae isolates and Acinetobacter spp. increased from 8.1 to 18.9% and from 14.1 to 17.4% respectively. Most of the S. aureus isolates were methicillin resistant. All the staphylococcal isolates were susceptible to vancomycin and linezolid. All the strains of K. pneumoniae isolated in 2009-2012 produced extended spectrum beta-lactamases. In 2012 7.8% the K. pneumoniae isolates were resistant to carbapenems. In 2012 25.5% of the Acinetobacter spp. isolates were susceptible to carbapenems and 70.2% were susceptible to cefoperazon/sulbactam.
T V
TV
Chernen'kaia
L A
LA
Borisova
I V
IV
Aleksandrova
S I
SI
Reĭ
O V
OV
Nikitina
D A
DA
Kosolapov
D000081:Acetamides / Q000627:therapeutic use; D000150:Acinetobacter / Q000187:drug effects / Q000254:growth & development; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology*; D002175:Candida / Q000187:drug effects / Q000254:growth & development; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology*; D015780:Carbapenems / Q000627:therapeutic use; D002438:Cefoperazone / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D016983:Enterococcus / Q000187:drug effects / Q000254:growth & development; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007362:Intensive Care Units; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000254:growth & development; D000069349:Linezolid; D008712:Methicillin / Q000627:therapeutic use; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D023303:Oxazolidinones / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*; D013407:Sulbactam / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use; D001618:beta-Lactamases
D000081:Acetamides; D000900:Anti-Bacterial Agents; D015780:Carbapenems; D023303:Oxazolidinones; D014640:Vancomycin; D002438:Cefoperazone; D001618:beta-Lactamases; D000069349:Linezolid; D008712:Methicillin; D013407:Sulbactam